

Patient ID SA00148231	Patient Name TESTINGRNV, ATLAS	Birth Date 1989-05-22	Gender F	Age 32
Order Number SA00148231	Client Order Number SA00148231	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 06 Oct 2021 12:00		

Congenital Lactic Acidosis Panel

Interpretation

MCR

This result decreases the likelihood but does not rule out the involvement of the genes evaluated in this panel.

Individuals may have a pathogenic variant in one of the interrogated genes that is not detectable by the methods utilized. Additionally, the clinical phenotype that is observed in this individual and/or family may be due to a pathogenic variant or variants in another gene not targeted by this test.

Individuals who have mitochondrial genome involvement may have a pathogenic variant not detectable by the methods utilized (e.g. variants present at a low heteroplasmy level or confined to tissues that were not tested).

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

A genetic consultation may be of benefit.

Result Summary

MCR

Negative

Result

MCR

No reportable variants were detected.

Test Description

MCR

Evaluation of 28 nuclear genes associated with congenital lactic acidosis and the mitochondrial genome

Specimen

MCR

WB Whole Blood

Resources

MCR

Disease specific information, including current therapies may be available at:

1. GeneReviews: <https://www.ncbi.nlm.nih.gov/books/NBK1116/>
2. <https://www.fda.gov/drugs>

Information regarding clinical trials, if available, can be found at the following sites:

1. ClinicalTrials.gov: <http://clinicaltrials.gov/ct2/search/advanced>

Method

MCR

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as select regions that have known pathogenic variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth >30X. Sensitivity is estimated at >99% for single nucleotide variants, >94% for indels up to 39 base pairs, >95% for deletions up to 75 base pairs and insertions up to 47 base pairs. NGS and/or a PCR-based quantitative method was performed to test for the presence of deletions and duplications in the genes analyzed. See the Genes Analyzed field for a list of genes tested.

NGS was also performed to test for the presence of variants within the mitochondrial genome (mtDNA) and to determine the mitochondrial haplogroup. Gel electrophoresis and NGS were performed to detect mtDNA deletions.

The haplogroup is only reported when clinically relevant and is computed using the software package HaploGrep (Hum Mutat 2011 Jan;32:25–32) and PhyloTree (Hum Mutat 2009 30(2):E386–E394). www.phylotree.org

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Patient ID SA00148231	Patient Name TESTINGRNV, ATLAS	Birth Date 1989-05-22	Gender F	Age 32
Order Number SA00148231	Client Order Number SA00148231	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 06 Oct 2021 12:00		

www.mayocliniclabs.com

CLADP for details regarding genes with regions not routinely covered.

Genes Analyzed

MCR

ACAD9, AGK, DLD, ECHS1, FBXL4, FLAD1, FOXRED1, GFER, HADHA, HADHB, HLCS, MRPL3, MRPS22, NDUFB11, NDUFS4, OGDH, PC, PDHA1, PDHX, PDP1, SLC25A19, SUCLG1, TMEM70, UQCRC2, VARS2, TPK1, SLC19A2, SLC19A3 and mitochondrial genome

Disclaimer

1 MCR

Clinical Correlations

An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at risk individuals.

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations

Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Please refer to the Targeted Genes and Methodology Details for the Congenital Lactic Acidosis Panel in the Special Instructions section of the Test Catalog for the most up to date list of genes included in this test.

Reclassification of Variants Policy

See www.mayocliniclabs.com

CLADP for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation

Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

Released By

MCR

Devin Oglesbee, Ph.D.

Received: 07 Oct 2021 16:12

Reported: 15 Oct 2021 11:16

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292



1-800-533-1710

Congenital Lactic Acidosis Panel

CLADP

PATIENT NAME TESTINGRNV, ATLAS				ORDER NUMBER L107000392
PATIENT ID SA00148231	DATE OF BIRTH 05/22/1989	AGE 32 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 10/6/2021, 12:00 PM	RECEIVED 10/7/2021, 4:12 PM	REPORTED 10/15/2021, 11:16 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00148231 CLIENT MRN SA00148231

TEST DESCRIPTION

Evaluation of 28 nuclear genes associated with congenital lactic acidosis and the mitochondrial genome

SPECIMEN

WB Whole Blood

RESULT SUMMARY

Negative

RESULT

No reportable variants were detected.

INTERPRETATION

This result decreases the likelihood but does not rule out the involvement of the genes evaluated in this panel.

Individuals may have a pathogenic variant in one of the interrogated genes that is not detectable by the methods utilized. Additionally, the clinical phenotype that is observed in this individual and/or family may be due to a pathogenic variant or variants in another gene not targeted by this test.

Individuals who have mitochondrial genome involvement may have a pathogenic variant not detectable by the methods utilized (e.g. variants present at a low heteroplasmy level or confined to tissues that were not tested).

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

A genetic consultation may be of benefit.

RESOURCES

Disease specific information, including current therapies may be available at:

1. GeneReviews: <https://www.ncbi.nlm.nih.gov/books/NBK1116/>
2. <https://www.fda.gov/drugs>

Information regarding clinical trials, if available, can be found at the following sites:

1. ClinicalTrials.gov: <http://clinicaltrials.gov/ct2/search/advanced>

METHOD

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as select regions that have known pathogenic variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the



1-800-533-1710

Congenital Lactic Acidosis Panel

CLADP

PATIENT NAME TESTINGRNV, ATLAS				ORDER NUMBER L107000392
PATIENT ID SA00148231	DATE OF BIRTH 05/22/1989	AGE 32 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 10/6/2021, 12:00 PM	RECEIVED 10/7/2021, 4:12 PM	REPORTED 10/15/2021, 11:16 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00148231 CLIENT MRN SA00148231

bases are covered at a read depth >30X. Sensitivity is estimated at >99% for single nucleotide variants, >94% for indels up to 39 base pairs, >95% for deletions up to 75 base pairs and insertions up to 47 base pairs. NGS and/or a PCR-based quantitative method was performed to test for the presence of deletions and duplications in the genes analyzed. See the Genes Analyzed field for a list of genes tested.

NGS was also performed to test for the presence of variants within the mitochondrial genome (mtDNA) and to determine the mitochondrial haplogroup. Gel electrophoresis and NGS were performed to detect mtDNA deletions.

The haplogroup is only reported when clinically relevant and is computed using the software package HaploGrep (Hum Mutat 2011 Jan;32:25-32) and PhyloTree (Hum Mutat 2009 30(2):E386-E394). www.phylotree.org

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See www.mayocliniclabs.com CLADP for details regarding genes with regions not routinely covered.

GENES ANALYZED

ACAD9, AGK, DLD, ECHS1, FBXL4, FLAD1, FOXRED1, GFER, HADHA, HADHB, HLCS, MRPL3, MRPS22, NDUFB11, NDUFS4, OGDH, PC, PDHA1, PDHX, PDP1, SLC25A19, SUCLG1, TMEM70, UQCRC2, VARS2, TPK1, SLC19A2, SLC19A3 and mitochondrial genome

DISCLAIMER

Clinical Correlations

An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at risk individuals.

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations

Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.



1-800-533-1710
Congenital Lactic Acidosis Panel

CLADP

PATIENT NAME TESTINGRNV, ATLAS				ORDER NUMBER L107000392
PATIENT ID SA00148231	DATE OF BIRTH 05/22/1989	AGE 32 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 10/6/2021, 12:00 PM	RECEIVED 10/7/2021, 4:12 PM	REPORTED 10/15/2021, 11:16 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00148231 CLIENT MRN SA00148231

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Please refer to the Targeted Genes and Methodology Details for the Congenital Lactic Acidosis Panel in the Special Instructions section of the Test Catalog for the most up to date list of genes included in this test.

Reclassification of Variants Policy

See www.mayocliniclabs.com CLADP for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation

Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

TEST CLASSIFICATION

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

RELEASED BY

Devin Oglesbee, Ph.D.

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus
Lab Director : WILLIAM G MORICE, II MD, PhD CLIA Certificate : 24D0404292

Address : 200 FIRST STREET SW
ROCHESTER MN 55905